Qube Research & Technologies (QRT)
XERS icon

Qube Research & Technologies (QRT)’s Xeris Biopharma Holdings XERS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.9M Sell
2,893,749
-1,220,676
-30% -$7.79M 0.02% 849
2026
Q1 		$23.9M Buy
4,114,425
+616,228
+18% +$4.09M 0.03% 784
2025
Q4 		$27.5M Buy
3,498,197
+223,363
+7% +$1.76M 0.03% 754
2025
Q3 		$26.7M Buy
3,274,834
+185,063
+6% +$1.23M 0.03% 757
2025
Q2 		$14.4M Buy
3,089,771
+1,245,188
+68% +$5.71M 0.01% 1071
2025
Q1 		$10.1M Buy
1,844,583
+1,384,975
+301% +$5.59M 0.01% 1136
2024
Q4 		$1.56M Buy
459,608
+218,037
+90% +$701K ﹤0.01% 1982
2024
Q3 		$688K Buy
241,571
+217,668
+911% +$559K ﹤0.01% 2169
2024
Q2 		$53.8K Sell
23,903
-154,659
-87% -$312K ﹤0.01% 2730
2024
Q1 		$395K Buy
+178,562
New +$462K ﹤0.01% 2663
2023
Q4 		– Sell
-53,883
Closed -$100K – 4804
2023
Q3 		$100K Buy
+53,883
New +$123K ﹤0.01% 2654
2022
Q3 		– Sell
-196,528
Closed -$303K – 3107
2022
Q2 		$303K Buy
196,528
+100,906
+106% +$213K ﹤0.01% 1591
2022
Q1 		$245K Sell
95,622
-26,005
-21% -$63.5K ﹤0.01% 1874
2021
Q4 		$356K Buy
+121,627
New +$263K ﹤0.01% 1720

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Qube Research & Technologies (QRT)'s XERS Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Xeris Biopharma Holdings (XERS) stake by 30% in Q2 2026, selling an estimated $7.79M and leaving 2,893,749 shares worth $22.9M. The position accounts for 0.02% of the portfolio, ranked #849.

Qube Research & Technologies (QRT) first reported a position in XERS in Q4 2021 and has held it in 14 quarters since. The position peaked at $27.5M in Q4 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Qube Research & Technologies (QRT) held 2,893,749 shares of Xeris Biopharma Holdings worth $22.9M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 1,220,676 Xeris Biopharma Holdings shares in Q2 2026, an estimated $7.79M.
  • Xeris Biopharma Holdings made up 0.02% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #849 holding.
  • Qube Research & Technologies (QRT) first reported a position in Xeris Biopharma Holdings in Q4 2021 and has held it in 14 quarters since.
  • Qube Research & Technologies (QRT)'s Xeris Biopharma Holdings position peaked at $27.5M in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.